Emcure Pharmaceuticals Ltd News

Why did Emcure Pharma share price rise 2% in overall muted market?

At 9:25 AM, Emcure Pharma share price continued to trade 1 per cent higher at ₹1,392, even as BSE Sensex trade flat with a negative bias at 85,509.78 levels.

Emcure targets pan-India obesity market with Poviztra semaglutide

As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities

Emcure Pharma shares slip 5% amid large trades; check all details here

According to Bloomberg data, 2.4 per cent equity or 4.64 million shares changed hands through multiple block deals. Buyers and sellers of the transactions were not known

Stocks to Watch today, Nov 18: PhysicsWallah, BSE, HCL Tech, Infosys, Paytm

Stocks to Watch Today, November 18, 2025: Tata Power Company, TVS Motor Company, Emcure Pharma, AstraZeneca Pharma, JSW Energy, JSW Cement, and WPIL are among the top stocks to remain in spotlight

Emcure Q2 PAT up 25%, domestic and international biz drive 13% revenue rise

The company's revenue from operations rose to Rs 2,269.8 crore, a 13.4 per cent increase from Rs 2,001.9 crore in Q2FY25

Emcure Pharma Q2 results: PAT rises 25% to ₹251 crore on strong sales

Emcure Pharmaceuticals on Tuesday reported a 25 per cent increase in profit after tax to Rs 251 crore in the September quarter, aided by strong sales performance across domestic and export markets. The drug firm posted a profit after tax (PAT) of Rs 202 crore during the July-September quarter of the last fiscal. Revenue from operations rose to Rs 2,270 crore in the second quarter as against Rs 2,002 crore in the year-ago period, Emcure Pharmaceuticals said in a statement. "We continue to augment our portfolio in all our focus markets through in-licensing and in-house developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry, enabling us to shape the market, Emcure Pharmaceuticals Chief Executive Officer and Managing Director Satish Mehta said. The company remains focused on delivering strong growth along with margin improvement in all key businesses, he added. Shares of the company were trading 3.90 per cent down at Rs

Novo Nordisk, Emcure Pharma to launch weight-loss drug under new brand

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

Top stocks to buy today: Shrikant Chouhan picks Emcure Pharma, ICICI Bank

Shrikant Chouhan, Head of Equity Research at Kotak Securities, has recommended buying shares of Emcure Pharmaceuticals and ICICI Bank today

Emcure Pharma shares gain as JM Financial initiates coverage; check target

JM Financial initiated coverage on Emcure Pharma with a 'Buy' rating and a target price of ₹1,740, citing its growth prospects

Emcure Pharma, Sanofi India shares edge higher; what's behind the move?

Emcure Pharma stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5 as the company announced a distribution and promotion partnership with Sanofi India

Emcure Pharma rises over 2% as USFDA issues Form 483 with Zero observations

Emcure Pharma share price rose in trade after the company announced that United States Food and Drug Administration (USFDA) issued Form 483 with zero observations for its Sanand, Ahmedabad unit.

Emcure Pharma shares dip after 2.4% stake change hands in block trades

Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE